- Citations, last 5 years
- 390
- Works, last 5 years
- 7
- h-index
- 60
- Scientists listed
- 0
- Grants since 2016
- 12
Grants received
2020–2023 · research · R44
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
Kai He · Oncoceutics (United States) · funded by National Institutes of Health
2020–2023 · research · R44
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
Kai He · Oncoceutics (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer
Wolfgang Oster · Oncoceutics (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer
Wolfgang Oster · Oncoceutics (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer
Joshua E. Allen · Oncoceutics (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer
Wolfgang Oster · Oncoceutics (United States) · funded by National Institutes of Health
2016–2020 · research · R01
Phase I/II Trial of ONC201 for the Treatment of Multiple Myeloma IND121,496 (01/05/2015)
Wolfgang Oster · Oncoceutics (United States) · funded by U.S. Food and Drug Administration
2016–2020 · research · R01
Phase I/II Trial of ONC201 for the Treatment of Multiple Myeloma IND121,496 (01/05/2015)
Wolfgang Oster · Oncoceutics (United States) · funded by U.S. Food and Drug Administration
2016–2020 · research · R01
Phase I/II Trial of ONC201 for the Treatment of Multiple Myeloma IND121,496 (01/05/2015)
Martin Stogniew · Oncoceutics (United States) · funded by U.S. Food and Drug Administration
2015–2021 · research · R44
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
Wolfgang Oster · Oncoceutics (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
Joshua E. Allen · Oncoceutics (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
Joshua E. Allen · Oncoceutics (United States) · funded by National Institutes of Health